Chinese General Practice ›› 2023, Vol. 26 ›› Issue (29): 3665-3673.DOI: 10.12114/j.issn.1007-9572.2023.0166
• Original Research • Previous Articles Next Articles
Received:
2022-08-17
Revised:
2023-04-12
Published:
2023-10-15
Online:
2023-05-26
Contact:
QIAO Zengyong
通讯作者:
乔增勇
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0166
组别 | 例数 | 年龄〔M(P25,P75),岁〕 | 性别(男/女) | 冠心病〔例(%)〕 | 高血压〔例(%)〕 | 心房颤动〔例(%)〕 | 吸烟史〔例(%)〕 | 收缩压〔M(P25,P75),mmHg〕 |
---|---|---|---|---|---|---|---|---|
Control组 | 46 | 78.0(74.8,81.3) | 25/21 | 46(100.0) | 26(56.5) | 5(10.8) | 10(21.7) | 135(124,146) |
CHF组 | 58 | 77.5(73.0,84.0) | 26/32 | 55 (94.8) | 36(62.0) | 35(60.3) | 14(24.1) | 131(122,141) |
检验统计量值 | -0.518b | 0.930a | - | 0.328a | 26.531a | 0.083a | -0.874b | |
P值 | 0.605 | 0.335 | 0.253 | 0.567 | <0.001 | 0.773 | 0.382 | |
组别 | 心率〔M(P25,P75),次/min〕 | WBC〔M(P25,P75),×109/L〕 | hs-CRP〔M(P25,P75),mg/L〕 | HDL〔M(P25,P75),mmol/L〕 | LDL〔M(P25,P75),mmol/L〕 | TG〔M(P25,P75),mmol/L〕 | ||
Control组 | 77(72,83) | 6.2(5.4,7.4) | 1.6(0.8,3.8) | 1.1(0.9,1.3) | 2.6(2.1,3.0) | 1.0(0.8,1.4) | ||
CHF组 | 85(76,97) | 5.7(4.6,8.6) | 5.4(2.3,11.5) | 1.1(0.9,1.3) | 2.2(1.8,2.8) | 0.8(0.6,1.1) | ||
检验统计量值 | -2.981b | -0.471b | -4.049b | -0.386b | -1.636b | -3.345b | ||
P值 | 0.003 | 0.637 | <0.001 | 0.699 | 0.102 | 0.001 | ||
组别 | 血肌酐〔M(P25,P75),μmol/L〕 | 尿素氮〔M(P25,P75),mmol/L〕 | 尿酸〔M(P25,P75),μmol/L〕 | ACEI/ARB 〔例(%)〕 | β受体阻滞剂〔例(%)〕 | 利尿剂〔例(%)〕 | ||
Control组 | 69.5(57.3,80.8) | 5.8(4.7,6.8) | 299.5(265.5,390.5) | 17(36.9) | 20(43.4) | 5 (10.8) | ||
CHF组 | 88.0(71.0,115.3) | 7.8(6.4,10.3) | 465.5(382.3,604.3) | 22(37.9) | 30(51.7) | 58(100.0) | ||
检验统计量值 | -4.285b | -4.864b | -5.429b | 0.010a | 0.699a | - | ||
P值 | <0.001 | <0.001 | <0.001 | 0.919 | 0.403 | <0.001 |
Table 1 Comparison of baseline data between the two groups of patients
组别 | 例数 | 年龄〔M(P25,P75),岁〕 | 性别(男/女) | 冠心病〔例(%)〕 | 高血压〔例(%)〕 | 心房颤动〔例(%)〕 | 吸烟史〔例(%)〕 | 收缩压〔M(P25,P75),mmHg〕 |
---|---|---|---|---|---|---|---|---|
Control组 | 46 | 78.0(74.8,81.3) | 25/21 | 46(100.0) | 26(56.5) | 5(10.8) | 10(21.7) | 135(124,146) |
CHF组 | 58 | 77.5(73.0,84.0) | 26/32 | 55 (94.8) | 36(62.0) | 35(60.3) | 14(24.1) | 131(122,141) |
检验统计量值 | -0.518b | 0.930a | - | 0.328a | 26.531a | 0.083a | -0.874b | |
P值 | 0.605 | 0.335 | 0.253 | 0.567 | <0.001 | 0.773 | 0.382 | |
组别 | 心率〔M(P25,P75),次/min〕 | WBC〔M(P25,P75),×109/L〕 | hs-CRP〔M(P25,P75),mg/L〕 | HDL〔M(P25,P75),mmol/L〕 | LDL〔M(P25,P75),mmol/L〕 | TG〔M(P25,P75),mmol/L〕 | ||
Control组 | 77(72,83) | 6.2(5.4,7.4) | 1.6(0.8,3.8) | 1.1(0.9,1.3) | 2.6(2.1,3.0) | 1.0(0.8,1.4) | ||
CHF组 | 85(76,97) | 5.7(4.6,8.6) | 5.4(2.3,11.5) | 1.1(0.9,1.3) | 2.2(1.8,2.8) | 0.8(0.6,1.1) | ||
检验统计量值 | -2.981b | -0.471b | -4.049b | -0.386b | -1.636b | -3.345b | ||
P值 | 0.003 | 0.637 | <0.001 | 0.699 | 0.102 | 0.001 | ||
组别 | 血肌酐〔M(P25,P75),μmol/L〕 | 尿素氮〔M(P25,P75),mmol/L〕 | 尿酸〔M(P25,P75),μmol/L〕 | ACEI/ARB 〔例(%)〕 | β受体阻滞剂〔例(%)〕 | 利尿剂〔例(%)〕 | ||
Control组 | 69.5(57.3,80.8) | 5.8(4.7,6.8) | 299.5(265.5,390.5) | 17(36.9) | 20(43.4) | 5 (10.8) | ||
CHF组 | 88.0(71.0,115.3) | 7.8(6.4,10.3) | 465.5(382.3,604.3) | 22(37.9) | 30(51.7) | 58(100.0) | ||
检验统计量值 | -4.285b | -4.864b | -5.429b | 0.010a | 0.699a | - | ||
P值 | <0.001 | <0.001 | <0.001 | 0.919 | 0.403 | <0.001 |
组别 | 例数 | LVEF(%) | LVESD(mm) | LVEDD(mm) | BNP(ng/L) | PAGln(μg/L) |
---|---|---|---|---|---|---|
Control组 | 46 | 67.5(62.0,71.0) | 29.5(27.0,31.0) | 48.0(45.0,50.0) | 50.3(18.5,110.7) | 37.8(14.0,50.5) |
CHF组 | 58 | 49.5(40.0,64.0) | 38.0(30.8,50.0) | 52.0(46.8,60.3) | 1 763.0(1 011.5,2 796.9) | 128.2(101.6,188.8) |
Z值 | -6.102 | -4.862 | -3.344 | -8.646 | -7.216 | |
P值 | <0.001 | <0.001 | 0.001 | <0.001 | <0.001 |
Table 2 Comparison of echocardiographic indexes,BNP and PAGln levels between the two groups
组别 | 例数 | LVEF(%) | LVESD(mm) | LVEDD(mm) | BNP(ng/L) | PAGln(μg/L) |
---|---|---|---|---|---|---|
Control组 | 46 | 67.5(62.0,71.0) | 29.5(27.0,31.0) | 48.0(45.0,50.0) | 50.3(18.5,110.7) | 37.8(14.0,50.5) |
CHF组 | 58 | 49.5(40.0,64.0) | 38.0(30.8,50.0) | 52.0(46.8,60.3) | 1 763.0(1 011.5,2 796.9) | 128.2(101.6,188.8) |
Z值 | -6.102 | -4.862 | -3.344 | -8.646 | -7.216 | |
P值 | <0.001 | <0.001 | 0.001 | <0.001 | <0.001 |
组别 | 例数 | Chao1指数 | Simpson指数 |
---|---|---|---|
Control组 | 46 | 1 023.35(879.50,1 289.55) | 0.083 9(0.060 4,0.130 0) |
CHF组 | 58 | 936.90(780.85,1 120.85) | 0.080 9(0.049 8,0.109 0) |
P值 | <0.05 | >0.05 |
Table 3 Comparison of α- diversity index of intestinal flora in both groups
组别 | 例数 | Chao1指数 | Simpson指数 |
---|---|---|---|
Control组 | 46 | 1 023.35(879.50,1 289.55) | 0.083 9(0.060 4,0.130 0) |
CHF组 | 58 | 936.90(780.85,1 120.85) | 0.080 9(0.049 8,0.109 0) |
P值 | <0.05 | >0.05 |
[1] |
中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志,2018,46(10):760-789. DOI:10.3760/cma.j.issn.0253-3758.2018.10.004.
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
许天昱,张宇辉,张健. 肠道菌群与心力衰竭的研究进展[J]. 中华心血管病杂志,2018,46(6):495-498. DOI:10.3760/cma.j.issn.0253-3758.2018.06.016.
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
乐世俊,王文晓,陶慧娟,等. 肠道菌群-TMA-TMAO代谢途径与心血管疾病的研究进展[J]. 中华心血管病杂志,2020,48(2):159-163. DOI:10.3760/cma.j.issn.0253-3758.2020.02.014.
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[1] | ZHANG Jin, DING Zhiguo, QI Shuo, LI Ying, LI Weiqiang, ZHANG Yuanyuan, ZHOU Tong. Relationship between Serum Thyroid Hormone Levels and Prognosis during Hospitalization in Heart Failure Patients [J]. Chinese General Practice, 2023, 26(33): 4125-4129. |
[2] | MA Yanyan, REN Fuxian, WANG Yu, GAO Dengfeng. The Prediction Value of (Neutrophil+Monocyte) /Lymphocyte Ratio on In-hospital Mortality of Heart Failure Patients [J]. Chinese General Practice, 2023, 26(30): 3791-3796. |
[3] | WEI Yurou, TIAN Jiaqing, XIAO Fangjun, HE Xianshun, ZHAN Zhiwei, WEI Tengfei, LIN Tianye, HE Mincong, WEI Qiushi. Effect of Huoxue Tongluo Capsule on Intestinal Flora of Rats with Steroid-induced Osteonecrosis of the Femoral Head [J]. Chinese General Practice, 2023, 26(29): 3674-3682. |
[4] | XIAO Liqi, YANG Li, CUI Saixian, ZHANG Yayuan, WANG Yulu, HE Yan. Advances in the Association of High Salt-induced Gut Microbiota Disturbances with Salt-sensitive Blood Pressure [J]. Chinese General Practice, 2023, 26(29): 3704-3709. |
[5] | FEI Sijie, ZHANG Qiang, LIU Fangfang, BAI Lu, SUN Caihong, XIN Caifeng. Correlation between Glycated Hemoglobin Variability and New-onset Atrial Fibrillation in Type 2 Diabetes Patients Combined with Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2023, 26(26): 3246-3251. |
[6] | CHEN Ruimin, LIU Fang, TAN Hong, HAN Shufang, CHEN Yingjian, SU Congcong. Effects of Dapagliflozin on the Expression of MicroRNA-423-5p and Cardiac Function in Patients with Type 2 Diabetes Mellitus and Chronic Heart Failure [J]. Chinese General Practice, 2023, 26(14): 1733-1738. |
[7] | FU Weiqiang, ZHOU Jianbo, WU Xiongjian, HUANG Caibin. Treatment Strategy of Nonalcoholic Fatty Liver Disease Targeting the Intestinal Microbiota [J]. Chinese General Practice, 2023, 26(06): 742-748. |
[8] | HU Huachao, CHEN Xianya, XIE Siyuan, XIA Zhen, XIAO Hua. Clinical Characteristics and Treatment of Atrial Fibrillation and Heart Failure: a Multicenter Survey [J]. Chinese General Practice, 2023, 26(05): 541-549. |
[9] | CHEN Ying, ZHENG Hui, HE Yu. Association between Nutritional Status and Prognosis in Elderly Patients with Heart Failure with Preserved Ejection Fraction and Coronary Heart Diseases [J]. Chinese General Practice, 2023, 26(03): 335-342. |
[10] | GAO Yan, LIANG Kun, LUAN Mingya, ZHANG Jianxin, XU Ning, LIU Nana, ZHANG Xiaoping, SHANG Gechu, LIU Kewei. Effect of Two Commonly Used Doses of Tolvaptan on the Prognosis of Elderly Patients with Chronic Heart Failure [J]. Chinese General Practice, 2023, 26(02): 233-240. |
[11] | CEN Qiuyu, PANG Rizhao, CUI Yanru, WEI Juanfang, ZHANG Anren. Advances in the Mechanism of Lactobacillus rhamnosus GG Improving Inflammatory Bowel Disease [J]. Chinese General Practice, 2022, 25(36): 4595-4600. |
[12] | LIU Xianling, HONG Jian, WANG Kai, QIAN Lijun, SUN Yan, MA Wenjie, LI Zhongming, XU Di. Progress in Clinical Treatment of Heart Failure with Preserved Ejection Fraction Combined with Depression [J]. Chinese General Practice, 2022, 25(33): 4196-4202. |
[13] | Fang HE, Fulan WANG, Liling XIE, Shuya LING, Mingchao XIAO. Application of TeamSTEPPS in the Management of Out-of-hospital Medication Safety for Patients with Chronic Heart Failure [J]. Chinese General Practice, 2022, 25(30): 3768-3774. |
[14] | Huahua HUANG, Tao TIAN, Dongmei ZHANG, Hong LIU, Xubo LI, Wenyuan MA. A Comparative Study of Four Nutritional Evaluation Methods in Prognostic Evaluation of Elderly Patients with Chronic Heart Failure [J]. Chinese General Practice, 2022, 25(24): 3029-3035. |
[15] | Dong AN, Shuren LI, Fei LUO, Xiao HAO. Research Progress of Sodium-glucose-cotransporter-2 Inhibitors in Patients with Heart Failure with Mildly Reduced Ejection Fraction [J]. Chinese General Practice, 2022, 25(21): 2680-2685. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||